Back to Top Skip to main content Skip to sub-navigation

DOD participates in new COVID-19 antibody combination prevention trial

Woman gets blood drawn Miranda Heilweil gets her blood drawn at Madigan Army Medical Center, Washington, one of five DOD sites where the STORM CHASER trial is studying the efficacy of an antibody product that could prevent COVID-19 in people who have been exposed to the virus within eight days. (U.S. Army photo by Janell Cain)

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | MHS Toolkits and Branding Guidance

While the Military Health System continues to support the development and distribution of COVID-19 vaccines to counter the ongoing public health threat of the disease, it’s investing in other efforts to counter the SARS-CoV-2 virus.

One of those includes evolving therapeutics as part of the U.S. government’s COVID-19 response through clinical trials of a long-acting antibody combination medicine to prevent COVID-19 among people who have been exposed to the disease.

The intramuscular long-acting antibody product, called AZD7442 and developed by AstraZeneca, is undergoing a phase III clinical trial at five Department of Defense sites to study its efficacy among eligible MHS beneficiaries who have recently been exposed to others with SARS-CoV-2 infection.

“This study will run for one year, although interim and primary analyses will likely occur much earlier in 2021,” said Dr. Simon Pollett, associate scientific director and COVID-19 research area director at the Uniformed Services University of the Health Science’s (USU) Infectious Diseases Clinical Research Program (IDCRP).

Under the name STORM CHASER, Pollett’s program is coordinating teams of physicians, nurses, pharmacists, and clinical research staff at Tripler Army Medical Center in Hawaii, Madigan Army Medical Center in Washington, William Beaumont Army Medical Center in Texas, Naval Medical Center Portsmouth in Virginia, and USU in Maryland. The lead investigators at these sites are Army Col. Viseth Ngauy, Army Col. Anjali Kunz, Dr. Gina Kubicz, Navy Lt. Cmdr. Tida Lee, and Army Lt. Col. Jeffrey Livezey, respectively.

This study is designed to prevent the development of illness in people who have been exposed to COVID-19 in care homes and sites with enhanced risk of disease transmission, under the sponsorship of AstraZeneca with support from the U.S. health information technology and clinical research firm IQVIA. IDCRP is supported through a cooperative agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine.

Primarily, STORM CHASER seeks to determine if the antibody injection can prevent COVID-19 in people who were exposed to the SARS-CoV-2 virus – which causes the disease – within the last eight days, but have not yet developed symptoms, explained Pollett. “This may include those exposed by household contacts, in crowded working conditions, in health care settings, and other scenarios,” he added.

A secondary objective of the study is examining whether the antibody injection can reduce viral shedding in those who may develop the disease after receiving the injection, said Pollett. Viral shedding occurs when the virus replicates inside the body and is released to the environment, making the host person contagious to others.

“Reduced viral shedding may perhaps correlate with reduced transmissibility, but this requires further study,” said Pollett.

STORM CHASER also aims to see if individuals who receive the AZD7442 injection after SARS-CoV-2 exposure experience less severe symptoms of COVID-19. Likewise, the clinical trial seeks to explore “sequencing of breakthrough virus to look at antibody escape mutations,” said Navy Capt. Timothy Burgess, IDRCP director. This will help determine whether AZD7442 protects across a range of SARS-CoV-2 strains, including newly emerged variants.

AZD7442 contains infection-fighting proteins called monoclonal antibodies that work to neutralize the virus, thus preventing COVID-19. Each dose is given once as two intramuscular shots in each gluteal region, within eight days of exposure.

If clinical trials are successful and the product receives emergency use authorization from the Food and Drug Administration, this investigational product would become another tool to defeat the COVID-19 pandemic. Two vaccines, by Pfizer-BioNTech and Moderna, are available to the U.S. population older than 16 and 18 years of age, respectively, under FDA’s EUA, with three more vaccines, including AstraZeneca’s, currently in clinical trials.

The vaccines work inside the body by triggering the immune system to make antibodies that will block or kill the SARS-CoV-2 spike protein if it enters the body, which results in immunity to coronavirus. They are given to healthy individuals who have not been exposed to the virus to protect them against getting seriously ill from the disease if they become infected or exposed, and studies are still being conducted to gauge their ability to keep people from spreading the virus.

AZD7442 may provide very rapid protection against COVID-19 in individuals who have been exposed because it is given while the virus is incubating, said Burgess. But those who have already received the COVID-19 vaccine are not eligible to participate in the study.

“The investigational product is intended to provide rapid immunity after exposure, with up to six months of protection thereafter,” said Burgess. “STORM CHASER is examining the efficacy of this.”

If the study is successful in achieving its objective of preventing COVID-19 after exposure, the hope, according to Pollett, is that transmission chains will also be stopped by preventing such COVID-19 cases, but further study is required.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense; under Contract No. W911QY-21-9-0001.

If interested in participating in the STORM CHASER trial - please contact Julia Rozman at: julia.rozman.ctr@usuhs.edu.

You also may be interested in...

After the ventilator COVID survivor advocates for vaccine

Article Around MHS
9/15/2021
Tim Harris is sedated while on a ventilator

Tim Harris, a mobilization and planning specialist, U.S. Army Medical Center of Excellence, is sedated while on a ventilator at Brooke Army Medical Center, Joint Base San Antonio-Fort Sam Houston, Texas, June 27, 2020.

Recommended Content:

Coronavirus

Army Medicine Europe Provides Additional COVID Vaccinations for Immune Compromised

Article Around MHS
9/13/2021
Franz Dietrich, a German local national assigned to Training Support Activity Europe, receives a COVID-19 vaccination at the 7th Army Training Command's (7ATC) Rose Barracks, Vilseck, Germany, May 4, 2021. The U.S. Army Health Clinics at Grafenwoehr and Vilseck conducted a "One Community" COVID-19 vaccine drive May 3-7 to provide thousands of appointments to the 7ATC community of Soldiers, spouses, Department of the Army civilians, veterans and local nationals employed by the U.S. Army. (U.S. Army photo by Markus Rauchenberger)

Army medical treatment facilities in Europe are now offering an additional dose of COVID vaccine for immune compromised beneficiaries.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts

The COVID-19 Pandemic: How Health Care Workers are Coping

Article
9/13/2021
a nurse helping a COVID-19 patient

For health care providers, experiencing the pandemic inside a hospital has brought

Recommended Content:

Coronavirus | Military Health Podcasts

Increased COVID Restrictions on the Pentagon Reservation

Article
9/8/2021
Military personnel wearing a face mask

Due to the increase in COVID-19 cases and positive test cases in the National Capital Region, the Pentagon Reservation will move to Health Protection Condition Bravo Plus (Bravo+)

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus

Digital health innovation emerges during COVID-19 pandemic

Article
8/31/2021
The Defense Health Agency’s Connected Health Branch was there to support, advise and deliver new health innovations throughout the pandemic. (Graphic courtesy of DHA Connected Health)

The DHA's Connected Health Branch was there to support, advise, and deliver new health innovations throughout the pandemic.

Recommended Content:

Connected Health | Coronavirus

As Fitness Tests Resume, Troops Seek Post-COVID Exercise Routines

Article
8/31/2021
Military personnel physically training

Keeping fit during pandemic proves hard for some.

Recommended Content:

Total Body Preventive Health and Total Force Fitness | Total Force Fitness | Physical Fitness | Coronavirus

COVID-19 Booster Shots

Infographic
8/27/2021
If you have an immune system that is moderately to severely compromised, the CDC recommends you may receive an additional dose of mRNA COVID-19 vaccine (Pfizer or Moderna). This would be at least 4 weeks after your second dose.

If you have an immune system that is moderately to severely compromised, the CDC recommends you may receive an additional dose of mRNA COVID-19 vaccine (Pfizer or Moderna). This would be at least 4 weeks after your second dose.

Recommended Content:

COVID-19 Vaccine Toolkit | Vaccine Eligibility | Coronavirus | COVID-19 Vaccine Efforts

Secretary of Defense Mandates COVID-19 Vaccinations for Service Members

Article
8/26/2021
An Army medic administers the COVID-19 vaccine to another soldier.

Secretary of Defense Lloyd J. Austin III yesterday issued a memorandum directing mandatory COVID-19 vaccinations for service members.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts

DOD Intends to Mandate Pfizer Vaccine, Pentagon Official Says

Article
8/25/2021
Pentagon Press Secretary John F. Kirby holds a press briefing, at the Pentagon, Washington, D.C.

Kirby said the health of DOD's military and civilian employees, families and communities is a top priority.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts

Maintaining Mission Readiness During a Pandemic

Article
8/24/2021
Gen. Place presents at HIMSS in Las Vegas.

DHA Director Army Lt. Gen. (Dr.) Ronald Place discussed the national security implications of the COVID-19 outbreak.

Recommended Content:

Coronavirus | Heroes Behind the Mask | Deployment Health

CSM Gragg Vaccine Statement

Video
8/24/2021
CSM Gragg speaks about COVID-19

CSM Gragg shares his personal story dealing with COVID and the loss associated with it and urges all to take precautions.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | Getting the COVID-19 Vaccine

LTG Place on Vaccine Importance

Video
8/17/2021
LTG Place on Vaccine Importance

LTG Place presents his concerns over those who are still unvaccinated during these unprecedented times. Take the right steps to prevent tragedy befalling your family and schedule your vaccine today at https://tricare.mil/vaccineappointments.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

Reform, COVID-19 Have Been Catalysts for Change in Military Medicine

Article
8/16/2021
Dr. Terry Adirim speaking to an audience at a conference

Healthcare is about taking care of people, so no amount of change or innovation is ever sufficient if modernization does not lead to helping patients, says acting ASDHA at HIMSS21 in Las Vegas.

Recommended Content:

Coronavirus | COVID-19 Vaccine Toolkit | Military Health System Transformation

Got Your 6: August 16, 2021

Video
8/16/2021
Got Your 6: August 16, 2021

‘Got Your 6’ is TRICARE’s COVID vaccine video series that delivers important information and updates, on days that end in ‘6.’ It includes the latest information about DOD vaccine distribution, the TRICARE health benefit, and vaccine availability. Got a question about ‘Got Your 6’? Send an email to dha.ncr.comm.mbx.dha-internal-communications@mail.mil Find your local military provider at tricare.mil/MTF, or go to tricare.mil/vaccineappointments and schedule yours today!

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

Lt. Gen. Place and Command Sgt. Maj. Gragg on Getting Vaccinated

Video
8/16/2021
DHA Logo with the text: Importance of Vaccinations Lt. Gen. Ronald J. Place & Command Sgt. Maj. Michael L. Gragg

DHA Director Lt. Gen. Ron Place and DHA Senior Enlisted Leader Command Sgt. Maj. Michael Gragg talk about how getting vaccinated against COVID-19 is more important than ever.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Efforts | Coronavirus | Getting the COVID-19 Vaccine
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 40

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.